Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPD vs DAPD Plus MMF in Treatment-Experienced HIV Patients
NCT00038272Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing DAPD + MMF Placebo with DAPD + MMF (2 arms). Primary endpoints: HIV-1 RNA levels at 48 weeks and Safety and side effects at 48 weeks. Status: completed.
02
Drugs
amdoxovirmycophenolate mofetil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00038272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038272.